Kratom Use, Synthetic Cannabinoids (K2), and Trends in the Drug Supply.
Publication/Presentation Date
9-1-2026
Abstract
Kratom and synthetic cannabinoids (SCs), often known as K2, are psychoactive substances gaining popularity, aided by a lack of regulation, despite serious health risks. Kratom is a plant-based substance containing mitragynine and 7-hydroxymitragynine, which cause opioid and stimulant effects. Users are at risk of opioid toxicity and withdrawal, as well as consequences of product contamination. SCs are cannabinoid receptor agonists despite a lack of structural similarity to cannabis. Adverse effects include increased rates of psychosis as well as seizures, stroke, and myocardial infarction, as well as dependent behaviors. SC regulation has limited effectiveness as new compounds often bypass existing policies.
Volume
53
Issue
3
First Page
431
Last Page
439
ISSN
1558-299X
Published In/Presented At
Kolosionek, T. J., & Amaducci, A. M. (2026). Kratom Use, Synthetic Cannabinoids (K2), and Trends in the Drug Supply. Primary care, 53(3), 431–439. https://doi.org/10.1016/j.pop.2026.03.004
Disciplines
Medicine and Health Sciences
PubMedID
42521376
Department(s)
Department of Emergency Medicine, Department of Emergency Medicine Faculty, Department of Emergency Medicine Residents, Toxicology Division, Fellows and Residents
Document Type
Article